InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 7, 2025
JENA, Germany, May 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its financial results for the three months ended March 31, 2025, and provided a business update.
Read more at globenewswire.com
